Cargolux, Europe's Largest Cargo Airline, to Cease Transporting Disposables

Regulations by 2FIRSTS.ai
Mar.07.2024
Cargolux, Europe's Largest Cargo Airline, to Cease Transporting Disposables
Cargolux Bans Disposable E-cigarettes in Response to Health and Environmental Concerns, Leading the Industry in Sustainable Practices.

According to a report from Wort on March 6th, Cargolux, the Luxembourg-based international cargo airline, has announced that it will cease transporting disposable e-cigarettes. This decision by Cargolux and its subsidiary, Cargolux Italia, is a proactive response to the growing public concern about the harmful effects of such products on health and the environment.

 

Cargolux stated that disposable e-cigarettes pose a significant risk to human health, particularly to the younger generation, "because they are marketed with enticing flavors." Additionally, due to the potential environmental threat they pose, these products have already been banned in other countries, "these devices contain lithium batteries, and since they are not recyclable, improper disposal could result in environmental risks."

 

The company's CEO, Richard Forson, stated that he hopes that this measure will help reduce the supply of these products in the market.

 

This ban reflects Luxembourg International Air Cargo's commitment to the environment, public health, and safety. Through this measure, we hope to help reduce the availability of these products in the market.

 

At the same time, Cargolux also hopes that this initiative will lead other logistics companies to take similar actions. More and more products are now being included in the company's list of items transported on its global network routes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.
Nov.14 by 2FIRSTS.ai
Japan Tobacco Announces Executive Leadership Changes Effective in 2026
Japan Tobacco Announces Executive Leadership Changes Effective in 2026
Japan Tobacco Inc. (JT) has announced a series of executive and board appointments effective from 2026, including the nomination of Takehiko Tsutsui—currently Executive Vice President at JT International—as President, CEO and Representative Director.
Nov.26
2Firsts Interview with IBVTA: UK Vape Tax May Weaken Harm Reduction Efforts
2Firsts Interview with IBVTA: UK Vape Tax May Weaken Harm Reduction Efforts
As the UK prepares to introduce its first-ever vape tax in 2026, questions are growing about how the measure will reshape the country’s harm reduction landscape. IBVTA tells 2Firsts that while it was not in favour of the new duty, it accepts that it is being implemented and is working with regulators to ensure a smooth rollout — warning, however, that higher costs could slow smokers’ transition to safer alternatives.
Oct.07
PMI Urges South Africa to Differentiate Smoke-Free Products from Cigarettes
PMI Urges South Africa to Differentiate Smoke-Free Products from Cigarettes
South Africa is drafting new tobacco legislation aimed at reducing smoking-related deaths and promoting harm reduction.PMI said smoke-free products such as nicotine pouches and heated devices could play a critical role in reducing harm. Patrik Hildingsson, PMI’s director for oral products communications, said South Africa is developing a new regulatory framework to recognise and regulate smoke-free products, calling it a “big change” for the industry.
Oct.22 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
Philip Morris International and an Italian Design Brand Launch Limited-Edition IQOS Collaboration, Debuting in Japan Before Expanding to 13 Travel Retail Markets
Philip Morris International and an Italian Design Brand Launch Limited-Edition IQOS Collaboration, Debuting in Japan Before Expanding to 13 Travel Retail Markets
Philip Morris International (PMI) has partnered with Italian design brand Seletti on a limited-edition IQOS collaboration, unveiled at Milan’s Pirelli HangarBicocca. The collection features two models, launching first in Japan before rolling out to 13 global travel retail markets. PMI says the partnership leverages design and cultural storytelling to advance its smoke-free transition.
Oct.28 by 2FIRSTS.ai